OHSU

IRB #

IRB00009741

Title

A phase II randomized, multicenter study of treatment-free remission in chronic myeloid leukemia in chronic phase (CML-CP) Patients who achieve and sustain MR4.5 after switching to nilotinib

Principal Investigator

Michael Heinrich

Study Purpose

The purpose of this study is to learn if the study drug, nilotinib, can be safely stopped being taken with no return of CML in patients who responded well on the treatment in the past.

Medical Condition(s)

chronic myeloid leukemia (CML)

Eligibility Criteria

Patients with chronic myeloid leukemia (CML) who have been on imatinib treatment for at least 1 year prior to study entry and have only a very small amount of leukemia cells remaining are eligible for the study.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

up to 364 weeks or 7 years

Minors Included

No

Contact

Nan Subbiah
503-494-4603
subbiahn@ohsu.edu

or

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Novartis Pharmaceuticals, Inc.

Recruitment End

04/11/2025

Compensation Provided

No


Go Back